Table 1 Characteristics of HCV antibody positive patients currently under follow-up in EuroSIDA

Sex

Female

992 (32.8%)

233 (23.5%)

443 (44.7%)

316 (31.9%)

0.1870

Male

2031 (67.2%)

524 (25.8%)

919 (45.2%)

588 (29.0%)

Age

Median (IQR)

44 (36 - 50)

47 (39 - 52)

47 (38 - 51)

39 (34 - 46)

<.0001

CD4 Cell Count

Median (IQR)

512 (340 - 712)

572 (413 - 753)

525 (347 - 723)

445 (273 - 640)

<.0001

Transmission Risk

MSM

387 (12.8%)

147 (38.0%)

151 (39.0%)

89 (23.0%)

<.0001

IDU

1836 (60.7%)

417 (22.7%)

909 (49.5%)

510 (27.8%)

Heterosexual

574 (19.0%)

123 (21.4%)

200 (34.8%)

251 (43.7%)

Other

226 (7.5%)

70 (31.0%)

102 (45.1%)

54 (23.9%)

Race

Non-White

259 (8.6%)

94 (36.3%)

123 (47.5%)

42 (16.2%)

<.0001

White

2764 (91.4%)

663 (24.0%)

1239 (44.8%)

862 (31.2%)

Region of EuroSIDA

South

719 (23.8%)

207 (28.8%)

391 (54.4%)

121 (16.8%)

<.0001

West C

437 (14.5%)

162 (37.1%)

224 (51.3%)

51 (11.7%)

North

353 (11.7%)

129 (36.5%)

186 (52.7%)

38 (10.8%)

East C

502 (16.6%)

137 (27.3%)

248 (49.4%)

117 (23.3%)

East

926 (30.6%)

108 (11.7%)

282 (30.5%)

536 (57.9%)

Argentina

86 (2.8%)

14 (16.3%)

31 (36.0%)

41 (47.7%)

HBsAg Status

Negative

2719 (89.9%)

681 (25.0%)

1212 (44.6%)

826 (30.4%)

0.0528

Positive

172 (5.7%)

52 (30.2%)

78 (45.3%)

42 (24.4%)

Unknown

132 (4.4%)

24 (18.2%)

72 (54.5%)

36 (27.3%)

Taking cART

No

467 (15.4%)

92 (19.7%)

191 (40.9%)

184 (39.4%)

<.0001

Yes

2556 (84.6%)

665 (26.0%)

1171 (45.8%)

720 (28.2%)

HIV RNA Viral Load(Among those taking cART)

<500copies/ml

2302 (90.1%)

645 (28.0%)

1079 (46.9%)

578 (25.1%)

<.0001

Interferon Treatment

Previously Exposed

800 (26.5%)

367 (45.9%)

397 (49.6%)

36 (4.5%)

<.0001